Who are PCV10 full dose's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Prevnar 20, PCV13 alone, Streptococcus pneumoniae serotype 3, Prevnar13, GSK1024850A (SynflorixTM), Pneumococcal vaccine GSK1024850A.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/pcv10-full-dose.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

PCV10 full dose — Competitive Intelligence Brief

PCV10 full dose (PCV10 full dose) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Pneumococcal conjugate vaccine. Area: Immunology.

marketed Pneumococcal conjugate vaccine Immunology Biologic Live · refreshed every 30 min

Target snapshot

PCV10 full dose (PCV10 full dose) — Epicentre. PCV10 is a pneumococcal conjugate vaccine that stimulates the immune system to produce antibodies against 10 serotypes of Streptococcus pneumoniae.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
PCV10 full dose TARGET	PCV10 full dose	Epicentre	marketed	Pneumococcal conjugate vaccine
Prevnar 20	pneumococcal 20-valent conjugate vaccine (PCV20)	Pfizer Inc.	marketed	Pneumococcal conjugate vaccine	Streptococcus pneumoniae capsular polysaccharides (20 serotypes)	2021-06-08
PCV13 alone	PCV13 alone	Korea University Guro Hospital	marketed	Pneumococcal conjugate vaccine	Streptococcus pneumoniae polysaccharide capsule (13 serotypes)
Streptococcus pneumoniae serotype 3	Streptococcus pneumoniae serotype 3	University of Oxford	marketed	Pneumococcal conjugate vaccine	Streptococcus pneumoniae serotype 3 capsular polysaccharide
Prevnar13	Prevnar13	GlaxoSmithKline	marketed	Pneumococcal conjugate vaccine	Streptococcus pneumoniae polysaccharide capsule (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F)
GSK1024850A (SynflorixTM)	GSK1024850A (SynflorixTM)	GlaxoSmithKline	marketed	Pneumococcal conjugate vaccine	Streptococcus pneumoniae polysaccharide antigens (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F)
Pneumococcal vaccine GSK1024850A	Pneumococcal vaccine GSK1024850A	GlaxoSmithKline	phase 3	Pneumococcal conjugate vaccine	Streptococcus pneumoniae capsular polysaccharides

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2033-06-01 — Prevnar 20 · US 8,895,024 · Composition of matter · US
2035-06-01 — Prevnar 20 · US 10,279,033 · Method of use · US

Sponsor landscape (Pneumococcal conjugate vaccine class)

GlaxoSmithKline · 12 drugs in this class
Sanofi Pasteur, a Sanofi Company · 2 drugs in this class
Korea University Guro Hospital · 1 drug in this class
Merck Sharp & Dohme LLC · 1 drug in this class
Papua New Guinea Institute of Medical Research · 1 drug in this class
Pfizer Inc. · 1 drug in this class
Sanofi · 1 drug in this class
University of Minnesota · 1 drug in this class
University of Oxford · 1 drug in this class
Vabiotech · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). PCV10 full dose — Competitive Intelligence Brief. https://druglandscape.com/ci/pcv10-full-dose. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab